TY - JOUR
T1 - Cardiac changes in pediatric cancer survivors
AU - Mokshagundam, Deepa
AU - Olivieri, Laura J.
AU - McCarter, Robert
AU - Kim, Aerang
AU - Sable, Craig A.
AU - Spurney, Christopher F.
AU - Dham, Niti
N1 - Funding Information:
Funding This study was funded by a Pilot Award Grant from the Clinical and Translational Science Institute at Children’s National Medical Center and in part by the National Institute of Health (NHLBI, Prime Award No. R01HL125918-01).
Publisher Copyright:
© 2020 Journal of Investigative Medicine. All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Cardiac damage from chemotherapy is a known phenomenon leading to significant morbidity and mortality in the cancer surviving population, and identifying high-risk pediatric patients early is challenging. The purpose of this pilot study was to evaluate whether echo strain, cardiac MRI (CMR), and serum biomarkers are more sensitive methods for detecting cardiac toxicity than standard echo and to examine the relationship between biomarkers in patients without decreased systolic function as determined by standard echo. In this pilot study, we prospectively enrolled pediatric subjects after completion of anthracycline inclusive chemotherapy. Each subject underwent a post-Treatment echocardiogram (standard with strain), serum biomarkers (N-Terminal brain natriuretic peptide (NT-pro-BNP) and interleukin 1 receptor-like 1 protein (ST2)), and CMR (standard and extracellular volumes (ECVs)). We correlated the markers using Pearson correlation. We enrolled 30 subjects, 11F/19M, aged 8-21 years. Cumulative anthracycline dose (CAD) correlated with BNP (p=0.06), CMR ECV 4-chamber (p=0.05) and sagittal (p=0.01), and mitral valve E/A (p=0.02). BNP correlated with CMR ECV 4-chamber (p=0.001) and sagittal (p=0.001) and with echo average longitudinal strain (ALS) (p=0.05). This study demonstrated a significant correlation of CAD with BNP and CMR ECV. There was also a significant correlation of NT-pro-BNP with CMR ECV and ALS. Combining these parameters with standard echo has the potential to identify high-risk patients early. Further studies are needed for long-Term follow-up and management in this vulnerable population.
AB - Cardiac damage from chemotherapy is a known phenomenon leading to significant morbidity and mortality in the cancer surviving population, and identifying high-risk pediatric patients early is challenging. The purpose of this pilot study was to evaluate whether echo strain, cardiac MRI (CMR), and serum biomarkers are more sensitive methods for detecting cardiac toxicity than standard echo and to examine the relationship between biomarkers in patients without decreased systolic function as determined by standard echo. In this pilot study, we prospectively enrolled pediatric subjects after completion of anthracycline inclusive chemotherapy. Each subject underwent a post-Treatment echocardiogram (standard with strain), serum biomarkers (N-Terminal brain natriuretic peptide (NT-pro-BNP) and interleukin 1 receptor-like 1 protein (ST2)), and CMR (standard and extracellular volumes (ECVs)). We correlated the markers using Pearson correlation. We enrolled 30 subjects, 11F/19M, aged 8-21 years. Cumulative anthracycline dose (CAD) correlated with BNP (p=0.06), CMR ECV 4-chamber (p=0.05) and sagittal (p=0.01), and mitral valve E/A (p=0.02). BNP correlated with CMR ECV 4-chamber (p=0.001) and sagittal (p=0.001) and with echo average longitudinal strain (ALS) (p=0.05). This study demonstrated a significant correlation of CAD with BNP and CMR ECV. There was also a significant correlation of NT-pro-BNP with CMR ECV and ALS. Combining these parameters with standard echo has the potential to identify high-risk patients early. Further studies are needed for long-Term follow-up and management in this vulnerable population.
KW - biomarkers
KW - cardiomyopathies
KW - drug-related side effects and adverse reactions
KW - echocardiography
KW - leukemia
UR - http://www.scopus.com/inward/record.url?scp=85090845198&partnerID=8YFLogxK
U2 - 10.1136/jim-2020-001373
DO - 10.1136/jim-2020-001373
M3 - Article
C2 - 32868378
AN - SCOPUS:85090845198
SN - 1081-5589
VL - 68
SP - 1364
EP - 1369
JO - Journal of Investigative Medicine
JF - Journal of Investigative Medicine
IS - 8
ER -